Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT).

@article{Dery2016BaselineCA,
  title={Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT).},
  author={Jean Pierre Dery and Shamir R. Mehta and Harold N. Fisher and Xiang Zhang and Yajun Emily Zhu and Robert C. Welsh and Shahar Lavi and Tomas Cieza and M. A. Henderson and Sohrab Lutchmedial and Anthony Della Siega and Asim N. Cheema and Brian Y.L. Wong and Andr{\'e} Kokis and Payam Dehghani and Shaun G. Goodman},
  journal={American heart journal},
  year={2016},
  volume={181},
  pages={
          26-34
        }
}
BACKGROUND Contemporary use of dual antiplatelet therapy and consistency with guideline recommendations in acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI) have not been well characterized. METHODS The COAPT was a prospective, observational, multicenter, longitudinal study of patients with myocardial infarction (MI) undergoing PCI. Baseline characteristics, treatment patterns, processes of care, factors associated with switching to and from novel adenosine… Expand
Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.
TLDR
Based on this meta-analysis of observational and randomized studies, prasugrel appears to be equivalent or superior to ticagrelor in patients with ACS undergoing PCI on the 30-day follow up, and larger randomized trials with longer follow-ups are needed to establish superiority. Expand
Dual antiplatelet therapy in myocardial infarction with non-obstructive coronary artery disease - insights from a nationwide registry.
  • F. Montenegro Sá, R. Carvalho, +5 authors J. Morais
  • Medicine
  • Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • 2020
TLDR
Beyond sinus rhythm, the variables presented as independent predictors for DAPT use identify subgroups of patients who are classified as more prone to thrombotic events. Expand
Dual antiplatelet therapy in non-ST elevation acute coronary syndromes at Veterans Affairs Hospitals
TLDR
Among NSTEACS patients undergoing coronary angiography, early DAPT was not associated with improvement of outcomes but was associated with delays in surgical revascularisation. Expand
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
TLDR
The trial shows that early de-escalation of antiplatelet treatment can be considered as an alternative approach in patients with acute coronary syndrome managed with PCI and was non-inferior to standard treatment with prasugrel at 1 year after PCI. Expand
Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
TLDR
It is suggested that prasugrel might have a better efficacy profile than ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI), but this advantage was only seen in pooled observational studies and is likely to be affected by selection bias. Expand
Smoking and Outcomes Following Guided De-escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: A Substudy from the Randomized TROPICAL-ACS Trial.
TLDR
Guided DAPT de-escalation appears to be equally safe and effective in smokers and non-smokers and Regardless of smoking status and especially for those patients deemed unsuitable for one year of potent platelet inhibition this D APT strategy might be used as an alternative antiplatelet treatment regimen. Expand
Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial
TLDR
Treatment effects of guided de-escalation for P2Y12 inhibitors depend on patient's age with younger patients deriving a significant net clinical benefit, while in the elderly, this should be further investigated due to the limited sample size. Expand
Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction
TLDR
Among patients with ST-segment-elevation myocardial infarction and multivessels disease, complete revascularization with multivessel PCI consistently reduces major cardiovascular events in patients undergoing an initial pharmacoinvasive strategy as well as in those undergoing primary PCI. Expand
Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
TLDR
CYP2C 19*2 and CYP2C19*17 carrier status correlates with PR in ACS patients treated with clopidogrel and thus might be useful for pre-selecting patients who will and who may not be suitable for PGDE of anti-platelet treatment. Expand
Impact of provincial and national implementation strategies on P2Y12 inhibitor utilization for acute coronary syndrome in the elderly: an interrupted time series analysis from 2008 to 2018
TLDR
National guideline updates and drug coverage by a publicly funded medication plan significantly improved P2Y12 inhibitor utilization in patients managed with percutaneous intervention, coronary artery bypass grafting, and medically following national antiplatelet therapy guidelines. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study
TLDR
In this observational study, ADP receptor inhibitor switching does not appear to be significantly associated with increased hazard of MACE, bleeding, or continuation on the higher potency agent. Expand
Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research.
TLDR
TransSLATE-ACS is a prospective observational study that will track up to 17,000 MI patients managed with PCI, from the inhospital to outpatient settings for up to 12 months postdischarge to provide a comprehensive picture of current treatment patterns and outcomes in routine clinical practice. Expand
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry
TLDR
In everyday practice in Switzerland, prasugrel is predominantly used in younger patients with STEMI undergoing primary PCI, and a propensity score-matched analysis suggests a mortality benefit from pr asugrel compared with clopidogrel in these patients. Expand
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
TLDR
In this real world population of patients who underwent urgent or elective PCI, prasugrel was used mainly in patients with ACS, while it was avoided in patientsWith characteristics indicating increased bleeding risk, probably because of patient selection. Expand
Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective.
TLDR
There has been a temporal increase in ADPri use compared with previous national experience and an increased uptake of newer ADPri agents in routine Canadian practice. Expand
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States
TLDR
The different patient characteristics between prasugrel- and clopidogrel-treated patients suggest physicians are more selective in choosing patients for pr asugrel than recommended in the prAsugrel USPI, and after adjustment for these differences, 30 and 90 day AMI rehospitalization rates were lower for prasUGrel- treated patients compared to clipidog Rel-treated Patients. Expand
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
TLDR
It is suggested that 600 mg of clopidogrel may not be able to achieve an optimal PR inhibition in STEMI patients undergoing PCI and more potent drugs may be preferred. Expand
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel – the European MULTIPRAC Registry
TLDR
A steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel suggests that pre-hospital loading with thienopyridines is confined to low-risk patients. Expand
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes.
TLDR
Although early use of clopidogrel therapy has increased over time across the spectrum of ACS, a significant proportion of eligible patients still do not receive this evidence-based therapy and there is a need to optimize the use of proven antiplatelet therapies to improve clinical outcome. Expand
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
TLDR
The findings support deferring treatment with prasugrel until a decision is made about revascularization in patients with NSTEMI undergoing angiography within 48 h of admission. Expand
...
1
2
3
...